Clinical trial of gemcitabine injection in combination with tegafur, gimeracil and oteracil porassium capsules in the treatment of patients with pancreatic cancer
10.13699/j.cnki.1001-6821.2018.09.009
- VernacularTitle:吉西他滨注射剂联合替吉奥胶囊治疗胰腺癌的临床研究
- Author:
An-Bao XU
1
;
Shun-Li JI
;
Run-Zhou NI
;
Ming-Bing XIAO
Author Information
1. 南通大学附属医院药学部
- Keywords:
gemcitabine;
tegafur;
pancreatic cancer;
natural killer T cell;
T cell subgroup;
interferon-γ
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(9):1039-1041,1059
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of gemcitabine injection in combination with tegafur,gimeracil and oteracil porassium capsules in the treatment of pancreatic cancer.Methods A total of 60 patients with pancreatic cancer were randomly divided into control group (n =30) and treatment group (n =30).The control group was given intravenous infusion of gemcitabine injection (1000 mg · m-2,30 min) on the first,eighth and fifteenth day of treatment.On the basis of the control group,the treatment group was received oral administration of tegafur,gimeracil and oteracil porassium capsules (80 mg · m-2 · d-1) on the first and fifteenth day of treatment.Both groups were treated for 4 cycles.The clinical efficacy,natural killer T cells (NKT),interferon-γ (IFN-γ),T lymphocyte subsets (CD3+,CD+,CD8+) level,and adverse drug reactions were compared.Results After treatment,the total effective rates of the treatment group and control group were 86.67％ (26 cases/30 cases) and 63.33％ (19 cases/30 cases),respectively,with significant difference (P ＜0.05).After treatment,there were significant differences between the treatment group and the control group in NKT [(16.61 ±1.26) ％ vs (14.04±1.59) ％,IFN-γ [(7.27±0.47) μ,g· L-1vs (5.30±0.90) μ,g · L-1],CD3+ [(70.02 ±4.0)％ vs (65.94 ± 5.56)％];CD4+ [(41.64 ± 2.41)％ vs (38.87 ± 2.30)％];CD8+ were [(36.77 ±1.75)％ vs (38.23 ± 1.62)％];CD4+/ CD8+ were(1.27 ±0.11 vs 1.15 ±0.08) (P＜0.05).The adverse drug reactions of the two groups were mainly nausea,vomiting,diarrhea,and granulocytes,The incidence sof adverse reactions of the treatment group and the control group were 20.00％ (6 cases/30 cases) and 23.33％ (7 cases/30 cases),respectively,without significant difference(P ＞ 0.05).Conclusion Gemcitabine injection in combination with tegafur,gimeracil and oteracil porassium capsules showed efficacy higher than gemcitabine alone in the treatment of pancreatic cancer,with a similar safety profile.
